Compare Panacea Biotech with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs SANOFI INDIA - Comparison Results

PANACEA BIOTECH     Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH SANOFI INDIA PANACEA BIOTECH/
SANOFI INDIA
 
P/E (TTM) x 12.2 35.1 34.9% View Chart
P/BV x 2.9 6.1 47.8% View Chart
Dividend Yield % 0.0 1.4 -  

Financials

 PANACEA BIOTECH   SANOFI INDIA
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-18
SANOFI INDIA
Dec-18
PANACEA BIOTECH/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs3646,840 5.3%   
Low Rs1294,630 2.8%   
Sales per share (Unadj.) Rs96.81,203.1 8.0%  
Earnings per share (Unadj.) Rs-12.4165.3 -7.5%  
Cash flow per share (Unadj.) Rs-2.9209.9 -1.4%  
Dividends per share (Unadj.) Rs084.00 0.0%  
Dividend yield (eoy) %01.5 0.0%  
Book value per share (Unadj.) Rs50.4963.6 5.2%  
Shares outstanding (eoy) m61.2523.03 266.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.54.8 53.4%   
Avg P/E ratio x-19.934.7 -57.3%  
P/CF ratio (eoy) x-86.427.3 -316.3%  
Price / Book Value ratio x4.96.0 82.2%  
Dividend payout %050.8 0.0%   
Avg Mkt Cap Rs m15,101132,078 11.4%   
No. of employees `0002.53.3 74.8%   
Total wages/salary Rs m1,5164,068 37.3%   
Avg. sales/employee Rs Th2,401.98,393.8 28.6%   
Avg. wages/employee Rs Th614.21,232.4 49.8%   
Avg. net profit/employee Rs Th-307.91,153.0 -26.7%   
INCOME DATA
Net Sales Rs m5,92827,708 21.4%  
Other income Rs m82897 9.2%   
Total revenues Rs m6,01028,605 21.0%   
Gross profit Rs m8456,235 13.6%  
Depreciation Rs m5851,027 57.0%   
Interest Rs m1,0067 14,368.6%   
Profit before tax Rs m-6646,098 -10.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m992,292 4.3%   
Profit after tax Rs m-7603,806 -20.0%  
Gross profit margin %14.322.5 63.4%  
Effective tax rate %-14.937.6 -39.5%   
Net profit margin %-12.813.7 -93.3%  
BALANCE SHEET DATA
Current assets Rs m5,60315,922 35.2%   
Current liabilities Rs m6,9106,235 110.8%   
Net working cap to sales %-22.035.0 -63.1%  
Current ratio x0.82.6 31.8%  
Inventory Days Days20664 323.4%  
Debtors Days Days8421 401.3%  
Net fixed assets Rs m9,9417,539 131.9%   
Share capital Rs m61230 26.7%   
"Free" reserves Rs m3,02621,962 13.8%   
Net worth Rs m3,08722,192 13.9%   
Long term debt Rs m5,7070-   
Total assets Rs m16,07629,839 53.9%  
Interest coverage x0.3872.1 0.0%   
Debt to equity ratio x1.80-  
Sales to assets ratio x0.40.9 39.7%   
Return on assets %1.512.8 12.0%  
Return on equity %-24.617.2 -143.6%  
Return on capital %3.927.5 14.2%  
Exports to sales %24.00-   
Imports to sales %17.50-   
Exports (fob) Rs m1,424NA-   
Imports (cif) Rs m1,040NA-   
Fx inflow Rs m1,6007,587 21.1%   
Fx outflow Rs m1,1317,145 15.8%   
Net fx Rs m469442 106.0%   
CASH FLOW
From Operations Rs m1,1803,739 31.6%  
From Investments Rs m553-731 -75.6%  
From Financial Activity Rs m-1,644-1,972 83.3%  
Net Cashflow Rs m901,036 8.7%  

Share Holding

Indian Promoters % 74.5 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 0.6 14.4 4.2%  
FIIs % 1.3 14.6 8.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 10.5 224.8%  
Shareholders   10,259 15,184 67.6%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   J.B.CHEMICALS  ALEMBIC LTD  WYETH LTD  CADILA HEALTHCARE  SUVEN LIFESCIENCES  

Compare PANACEA BIOTECH With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY19); Net Profit Up 12.6% (Quarterly Result Update)

May 8, 2019 | Updated on May 8, 2019

For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA 2017-18 Annual Report Analysis (Annual Result Update)

Apr 16, 2019 | Updated on Apr 16, 2019

Here's an analysis of the annual report of SANOFI INDIA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SANOFI INDIA. Also includes updates on the valuation of SANOFI INDIA.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

SANOFI INDIA Announces Quarterly Results (3QFY19); Net Profit Up 4.3% (Quarterly Result Update)

Mar 5, 2019 | Updated on Mar 5, 2019

For the quarter ended December 2018, SANOFI INDIA has posted a net profit of Rs 793 m (up 4.3% YoY). Sales on the other hand came in at Rs 7 bn (up 8.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Sep 20, 2019 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 8-QTR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS